JP2016522179A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522179A5 JP2016522179A5 JP2016509298A JP2016509298A JP2016522179A5 JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5 JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016509298 A JP2016509298 A JP 2016509298A JP 2016522179 A5 JP2016522179 A5 JP 2016522179A5
- Authority
- JP
- Japan
- Prior art keywords
- general formula
- tamoxifen
- derivative
- formula
- isomers
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ2013-308A CZ304553B6 (cs) | 2013-04-24 | 2013-04-24 | Deriváty tamoxifenu účinné proti nádorům, zejména s vyšší hladinou proteinu HER2 |
| CZPV2013-308 | 2013-04-24 | ||
| CZPV2014-66 | 2014-01-29 | ||
| CZ2014-66A CZ305571B6 (cs) | 2014-01-29 | 2014-01-29 | Deriváty tamoxifenu k léčbě neoplastických chorob, zejména s vyšší hladinou proteinu HER2 |
| PCT/CZ2014/000035 WO2014173374A1 (en) | 2013-04-24 | 2014-04-07 | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522179A JP2016522179A (ja) | 2016-07-28 |
| JP2016522179A5 true JP2016522179A5 (https=) | 2017-04-06 |
| JP6375091B2 JP6375091B2 (ja) | 2018-08-15 |
Family
ID=50677895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016509298A Expired - Fee Related JP6375091B2 (ja) | 2013-04-24 | 2014-04-07 | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9896466B2 (https=) |
| EP (1) | EP2989110B1 (https=) |
| JP (1) | JP6375091B2 (https=) |
| KR (1) | KR101764991B1 (https=) |
| CN (1) | CN105452265B (https=) |
| AU (1) | AU2014256546B2 (https=) |
| CA (1) | CA2909994C (https=) |
| CY (1) | CY1120821T1 (https=) |
| DK (1) | DK2989110T3 (https=) |
| EA (1) | EA029881B1 (https=) |
| ES (1) | ES2699099T3 (https=) |
| GE (2) | GEAP201813996A (https=) |
| HR (1) | HRP20181872T1 (https=) |
| HU (1) | HUE042239T2 (https=) |
| MD (1) | MD4626C1 (https=) |
| NZ (1) | NZ713589A (https=) |
| PL (1) | PL2989110T3 (https=) |
| PT (1) | PT2989110T (https=) |
| SI (1) | SI2989110T1 (https=) |
| UA (1) | UA116469C2 (https=) |
| WO (1) | WO2014173374A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX383279B (es) * | 2015-07-03 | 2025-03-13 | Bayer Cropscience Ag | Derivados de n-(1,3,4-oxadiazol-2-il)aril carboxamida con accion herbicida. |
| EA033155B1 (ru) * | 2015-07-03 | 2019-09-30 | Байер Кропсайенс Акциенгезельшафт | Гербицидно активные производные n-(тетразол-5-ил)арилкарбоксамида |
| CN108495618B (zh) * | 2016-07-12 | 2019-08-16 | 冰洲石生物科技公司 | 新的化合物及其用途 |
| AU2017312499B2 (en) | 2016-08-19 | 2023-02-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Selective estrogen-receptor modulators (SERMs) confer protection against photoreceptor degeneration |
| EP3330274A1 (en) * | 2016-12-01 | 2018-06-06 | Springtide Ventures s.r.o. | Compounds for treatment of senescence-related disorders |
| EP3612177A4 (en) | 2017-04-21 | 2021-01-13 | Lunella Biotech, Inc. | TARGETING HYPOXIC CARCINOUS STEM CELLS (SCC) USING DOXYCYCLINE: IMPLICATIONS FOR IMPROVING ANTI-ANGIOGENIC THERAPY |
| US11197872B2 (en) | 2017-04-21 | 2021-12-14 | Lunella Biotech, Inc. | Vitamin C and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (CSCs) |
| PH12019502594A1 (en) | 2017-05-19 | 2020-10-26 | Lunella Biotech Inc | Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| JP2021500374A (ja) | 2017-10-24 | 2021-01-07 | ルネラ・バイオテック・インコーポレーテッド | 標的フラビン含有酵素がミトコンドリア呼吸を阻害することにより癌幹細胞（ｃｓｃｓ）を排除するミトフラボスチン |
| WO2019104115A1 (en) | 2017-11-24 | 2019-05-31 | Lunella Biotech, Inc. | Triphenylphosphonium-derivative compounds for eradicating cancer stem cells |
| WO2019108729A1 (en) | 2017-12-01 | 2019-06-06 | Lunella Biotech, Inc. | Repurposcins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells |
| WO2019113210A1 (en) | 2017-12-05 | 2019-06-13 | Anthos Partners, Lp | Phosphonium-based ionic drug conjugates |
| US11559527B2 (en) | 2017-12-20 | 2023-01-24 | Lunella Biotech, Inc. | Targeting mitochondrial fission through mDIVI-1 derivatives |
| WO2020214754A1 (en) * | 2019-04-16 | 2020-10-22 | Lunella Biotech, Inc. | Alkyl-tpp compounds for mitochondria targeting and anti-cancer treatments |
| EP3753944A1 (en) | 2019-06-17 | 2020-12-23 | Institute Of Biotechnology Cas, V.V.I. | 3,5-bis(phenyl)-1h-heteroaryl derivatives as medicaments |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0551434B1 (en) * | 1990-10-01 | 1995-11-15 | The Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives and uses thereof |
| JP3635708B2 (ja) * | 1995-03-06 | 2005-04-06 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子 |
| TWI309571B (en) * | 2002-12-31 | 2009-05-11 | Ind Tech Res Inst | Delivery carrier for targeting cells haring over-expressed estrogen |
| JP4648319B2 (ja) * | 2003-08-22 | 2011-03-09 | アンティポディーン ファーマシューティカルズ インコーポレイティド | ミトコンドリアを標的とする抗酸化剤として使用されるミトキノン誘導体 |
| CN1997403A (zh) * | 2004-07-13 | 2007-07-11 | 奥里迪斯生物医学研究及开发有限责任公司 | 靶向线粒体的抗氧化剂在治疗肝病和上皮癌中的用途 |
| WO2009111846A1 (en) * | 2008-03-14 | 2009-09-17 | Stephen John Ralph | Mitochondrially delivered anti-cancer compounds |
| BRPI1014978A2 (pt) * | 2009-04-17 | 2019-07-02 | Colby Pharmaceutical Company | método de tratamento do câncer e composição farmacêutica. |
| WO2011129837A1 (en) * | 2010-04-16 | 2011-10-20 | Olema Pharmaceuticals, Inc. | Use of a 4-hydroxytoremifene prodrug for treatment of breast cancer |
-
2014
- 2014-04-07 US US14/786,710 patent/US9896466B2/en not_active Expired - Fee Related
- 2014-04-07 KR KR1020157030376A patent/KR101764991B1/ko not_active Expired - Fee Related
- 2014-04-07 EP EP14721738.4A patent/EP2989110B1/en active Active
- 2014-04-07 HU HUE14721738A patent/HUE042239T2/hu unknown
- 2014-04-07 SI SI201430928T patent/SI2989110T1/sl unknown
- 2014-04-07 HR HRP20181872TT patent/HRP20181872T1/hr unknown
- 2014-04-07 NZ NZ713589A patent/NZ713589A/en not_active IP Right Cessation
- 2014-04-07 EA EA201591918A patent/EA029881B1/ru unknown
- 2014-04-07 JP JP2016509298A patent/JP6375091B2/ja not_active Expired - Fee Related
- 2014-04-07 CA CA2909994A patent/CA2909994C/en active Active
- 2014-04-07 GE GEAP201813996A patent/GEAP201813996A/en unknown
- 2014-04-07 WO PCT/CZ2014/000035 patent/WO2014173374A1/en not_active Ceased
- 2014-04-07 PL PL14721738T patent/PL2989110T3/pl unknown
- 2014-04-07 PT PT14721738T patent/PT2989110T/pt unknown
- 2014-04-07 AU AU2014256546A patent/AU2014256546B2/en not_active Ceased
- 2014-04-07 DK DK14721738.4T patent/DK2989110T3/en active
- 2014-04-07 ES ES14721738T patent/ES2699099T3/es active Active
- 2014-04-07 MD MD20150117A patent/MD4626C1/ro not_active IP Right Cessation
- 2014-04-07 CN CN201480033316.9A patent/CN105452265B/zh not_active Expired - Fee Related
- 2014-04-07 UA UAA201510642A patent/UA116469C2/uk unknown
-
2015
- 2015-04-07 GE GEAP201513996A patent/GEP20186868B/en unknown
-
2018
- 2018-11-06 CY CY181101155T patent/CY1120821T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016522179A5 (https=) | ||
| JP6375091B2 (ja) | 腫瘍性疾患であって特に高ｈｅｒ２タンパク質レベルの腫瘍性疾患を治療するためのタモキシフェン誘導体 | |
| Tang et al. | Synthesis and biological evaluation of 2, 3-diaryl isoquinolinone derivatives as anti-breast cancer agents targeting ERα and VEGFR-2 | |
| KR20140008297A (ko) | 도파민성 안정제로서 유용한 프리도피딘의 듀테륨화된 유사체 | |
| AU2022205484B2 (en) | Pyridone multiple-membered ring derivatives and use thereof | |
| NO20054526L (no) | Forebygging og behandling av brystkreft med 4-hydroxy tamoxifen | |
| EP3416950A1 (en) | Max binders as myc modulators and uses thereof | |
| JP2014530181A5 (https=) | ||
| NO20061319L (no) | 5-arylpyrimidiner som anticancer legemidler | |
| Zbieg et al. | Discovery of GNE-502 as an orally bioavailable and potent degrader for estrogen receptor positive breast cancer | |
| JP2013523867A5 (https=) | ||
| Sahu et al. | Interaction of Ru-4′-(2-pyridyl)-2, 2′: 6′, 2 ″-terpyridine with diseased HER2 protein | |
| JP2010509306A5 (https=) | ||
| JP6423349B2 (ja) | Ｎ−置換３，４−ビス（カテコール）ピロール化合物、その調製、及びガンの治療のためのその使用 | |
| JP2019517474A5 (https=) | ||
| CN104262289A (zh) | 一种苯并噻唑衍生物及其抗肿瘤用途 | |
| CN102649778A (zh) | 喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途 | |
| Yu et al. | Discovery of potent and orally available small molecule inhibitors of the SOS1-KRAS interaction | |
| Corcoran | Studies toward the synthesis of radioactive tyrosine kinase inhibitors, steroidal antiestrogens, and indoles as probes of biological systems | |
| HK1216317B (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
| Kluckova et al. | 424 Role of the Ubiquinone Site of Complex II in Apoptosis Induction and Malignant Transformation | |
| Erturk et al. | 426 Distinct MiRNA Expression Patterns in Among Breast Tumors of Patients Carried and Non-carried Germ-line BRCA Mutations | |
| Fernandez-Nogueira et al. | 423 Acquisition of Resistance to Anti-Her2 Therapies Promotes a Different Microenvironment Crosstalk Capability | |
| HK1243598B (en) | Combination therapies | |
| WO2015196312A1 (es) | Moléculas inhibidoras del receptor lox-1 y su incidencia directa en el control de la progresión tumoral en diversos tipos de cáncer humanos |